Inclusion Criteria:

Part A:

- Subjects with advanced or metastatic solid tumors who have either progressed on
standard therapy or for whom standard therapy is not known

Part B:

- Subjects with advanced or metastatic gastroesophageal cancer, HRPrC, HNSCC, or PRCC
who have either progressed on standard therapy, or for whom standard therapy is not
known. Eighteen (18) subjects each with gastroesophageal cancer, HRPrC, and HNSCC
will be treated. Subjects with PRCC (up to 18) will be enrolled as feasible

- Tumor paraffin tissue block or 6-10 unstained slides from the tumor tissue block must
be provided

- Subjects with HRPrC must have either measurable disease or rising PSA levels (≥3
consecutive rising levels with at least 1 week interval and with PSA level ≥5 mg/ml).
All other subjects must have measurable disease as assessed by CT or MRI

Exclusion Criteria:

- Know brain metastases

- Uncontrolled or significant cardiovascular disease

- Retinal atrophy